Loading clinical trials...

To Evaluate the Efficacy and Safety of ALC-2203 in Patients With Acute Bronchitis | Clinical Trials | Clareo Health

COMPLETEDPHASE2

To Evaluate the Efficacy and Safety of ALC-2203 in Patients With Acute Bronchitis

A Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Multicenter, Dose-finding, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of ALC-2203 in Patients With Acute Bronchitis

NCT07061925•Korea Arlico Pharm. Co., Ltd

View on ClinicalTrials.gov

Summary

Eligibility

Age

19 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Male and female participants aged 19 years or older.
•2. Patients diagnosed with acute bronchitis with:
•* A Bronchitis Severity Score (BSS) of ≥ 5 at Visit 2.
•* A sputum subscore of at least 1 at Visit 2.
•3. Onset of acute bronchitis symptoms within 48 hours prior to Visit 2.
•4. Patients who voluntarily agree to participate

Exclusion Criteria

•1. Patients who, in the opinion of the investigator, have severe respiratory diseases such as allergic asthma, chronic bronchitis, or asthma
•2. Patients who are currently taking, or are expected to take during the study period, antitussive or expectorant medications containing agents such as codeine or dextromethorphan
•3. Patients who have participated in another clinical trial within 4 weeks prior to screening

Locations (1)

Konkuk University Medical Center

Seoul, South Korea

Key Dates

Start Date

April 23, 2025

Primary Completion Date

November 21, 2025

Completion Date

November 26, 2025

Last Updated

December 24, 2025

Enrollment

169

ACTUAL participants

Conditions

Acute Bronchitis

Interventions

ALC-2203-1

DRUG

ALC-2203-2

DRUG

ALC-2203-AC

DRUG

Placabo

DRUG

A Study to Evaluate the Efficacy and Safety of DW5121 Compared to DW51211 and DW51212

NCT07093697

Acute Bronchitis

View study

COMPLETEDNA

Treatment of Adults With Acute Bronchitis in the Primary Healthcare Setting

NCT06142994

Acute Bronchitis

View study

COMPLETEDPHASE4

Effectiveness of Antitussives, Anticholinergics and Honey Versus Usual Care in Adults With Acute Bronchitis.

NCT03738917

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 24, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

To Evaluate the Efficacy and Safety of ALC-2203 in Patients With Acute Bronchitis

Inclusion Criteria

Exclusion Criteria

A Study to Evaluate the Efficacy and Safety of DW5121 Compared to DW51211 and DW51212

Treatment of Adults With Acute Bronchitis in the Primary Healthcare Setting

Effectiveness of Antitussives, Anticholinergics and Honey Versus Usual Care in Adults With Acute Bronchitis.

Efficacy and Safety of Intramuscular Injection of Xiyanping Injection in the Treatment of Acute Bronchitis in Children

The Development and Testing of a Scaling Strategy for a Community-Based Primary Care Antimicrobial Stewardship Program

Effect of Supplementation With Vitamin D on the Acute Bronchitis Prevention During the First Year of Life